New Study: Semaglutide in Ozempic Reduces Risk of Serious Kidney Outcomes, Major Cardiovascular Events, and Death for Diabetes Patients with Chronic Kidney Disease
Findings from the FLOW trial show semaglutide significantly reduces risks for diabetes patients with CKD.
New study reveals semaglutide in Ozempic reduces risk of serious kidney outcomes, major cardiovascular events, and death for diabetes patients with chronic kidney disease.
Semaglutide, a GLP-1 compound in Ozempic, has shown success in treating Type 2 diabetes and CKD.
In a groundbreaking development for diabetes patients with chronic kidney disease, new findings from the FLOW trial reveal that semaglutide, a compound found in Ozempic, significantly reduces the risk of serious kidney outcomes, major cardiovascular events and death. The GLP-1 franchise of Novo Nordisk, specifically semaglutide has shown remarkable success in treating patients with Type 2 diabetes and chronic kidney disease (CKD). According to Michael Radin, Executive Medical Director at Novo Nordisk,
Semaglutide reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic kidney disease in a major clinical trial.
The research was presented at a European Renal Association meeting in Stockholm on Friday and simultaneously published in The New England Journal of Medicine.
Novo Nordisk, the maker of Ozempic, stopped the trial early due to its success.
Semaglutide stands out among available options for treating patients with Type 2 diabetes and CKD due to its ability to address both kidney health and cardiovascular risks.
Accuracy
]Semaglutide reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic kidney disease[
Semaglutide helped reduce the risk of major cardiovascular events by 18% and reduced the risk of all-cause mortality by 20%
The findings could transform how doctors treat some of the sickest patients with chronic kidney disease.
Novo Nordisk’s GLP-1 franchise, specifically semaglutide, has shown significant success in treating patients with Type 2 diabetes and chronic kidney disease (CKD).
Semaglutide helped reduce the risk of major cardiovascular events by 18% and reduced the risk of all-cause mortality by 20% in the FLOW trial.
The rate of kidney function decline over time was significantly slower with semaglutide versus placebo, as measured by estimated glomerular filtration rate (eGFR).
Semaglutide stands out among available options for treating patients with Type 2 diabetes and CKD due to its ability to address both kidney health and cardiovascular risks.
Novo Nordisk is planning to seek updated approvals in kidney disease for semaglutide by the end of 2024.
Weekly injections of semaglutide medications like Ozempic significantly reduce the risk of serious kidney outcomes, major cardiovascular events and death among people who have type 2 diabetes and chronic kidney disease.
The new study found even broader related benefits of semaglutide treatment among people with diabetic kidney disease. Kidney function declined more slowly overall, the risk of major cardiovascular events such as heart attack was 18% lower and the risk of death from any cause was 20% lower.
Semaglutide, the compound in Ozempic and Wegovy, reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic kidney disease in a major clinical trial.
Accuracy
]The new study found even broader related benefits of semaglutide treatment among people with diabetic kidney disease.[
]Kidney function declined more slowly overall, the risk of major cardiovascular events such as heart attack was 18% lower and the risk of death from any cause was 20% lower.[
]Semaglutide helped reduce the risk of major cardiovascular events by 18% and reduced the risk of all-cause mortality by 20%.[
The primary composite endpoint was reduced by 24% compared to placebo, with a number needed to treat of 20 over three years.
Semaglutide reduced the risk of major kidney events and death from cardiovascular causes in type 2 diabetes patients with chronic kidney disease.
The safety and efficacy seen in the trial provide a rationale for combining semaglutide with other proven therapies as initial therapeutic options.
Semaglutide stands out among available options for treating patients with Type 2 diabetes and CKD due to its ability to address both kidney health and cardiovascular risks.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(100%)
None Found At Time Of
Publication
Fallacies
(95%)
The author provides a clear and concise description of the results of a clinical trial. There are no explicit fallacies found in the text. However, there is an appeal to authority as the author cites the New England Journal of Medicine and mentions that the findings have been published in conjunction with a presentation at the European Renal Association meeting.
][The trial was stopped early for efficacy after a median follow-up of 3.4 years.][] The author states that the trial was stopped early for efficacy, but does not provide any evidence or reasoning to support this claim. This statement is not a fallacy, but it could be considered misleading if taken out of context.
The safety and efficacy seen in the trial also provide a rationale for combining semaglutide with the other proven therapies as initial therapeutic options in this patient population.
